
Patient groups urge FDA to reconsider govorestat rejection
The US Food and Drug Administration’s (FDA) decision not to approve govorestat, a central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI) for Classic Galactosemia, has been met with criticism from patient groups. Govorestat is the only investigational treatment to be evaluated for Galactosemia, a rare genetic disease that can be… Read More
